[144] Krystal Biotech, Inc. SEC Filing

Rhea-AI Filing Summary

The Form 144 filing relates to a proposed sale of 2,216 MYTE common shares (approx. market value $16,287.60) through Morgan Stanley Smith Barney on or about 07 July 2025. The seller acquired the shares on 30 June 2025 via restricted stock units granted by the issuer, MYT Netherlands Parent B.V. (MYTE). A prior Rule 10b5-1 sale of 10,000 shares on 14 May 2025 for $100,457 is also disclosed. The proposed sale represents roughly 0.0016 % of the company’s 136,374,256 shares outstanding, indicating an immaterial impact on the public float. No additional financial metrics, earnings data, or corporate developments accompany the notice. The signer certifies no undisclosed material adverse information. Overall, this is a routine administrative filing signalling a minor potential insider transaction rather than a strategic corporate event.

Insights

Equity Analyst

TL;DR: 2,216-share Form 144 sale; negligible at 0.0016 % float—insider activity immaterial to valuation.

The filing authorises the resale of 2,216 MYTE shares, valued at only $16k, versus a >136 million share count. Such volume will not alter supply-demand dynamics nor signal a major shift in insider sentiment, especially given the shares were recently vested RSUs. Investors typically monitor larger clustered sales or programmatic 10b5-1 activity; here, the prior 10,000-share May sale (£100k) is still a fraction of float. I view the disclosure as neutral; it neither improves nor worsens the investment thesis.

Corporate Governance Specialist

TL;DR: Routine compliance filing; confirms seller’s Rule 10b5-1 certification, no red flags spotted.

The notice reiterates standard certifications: absence of undisclosed adverse information and acknowledgment of criminal liability for misstatements. Inclusion of the 10b5-1 plan date maintains transparency. No accelerated or concentrated disposals are evident. Therefore, governance risk remains unchanged, and investors should treat this as ordinary course compliance.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	3583375.00	28898680	07/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/31/2017	Founders Shares	Issuer			25000	03/31/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many MYTE shares are being sold under this Form 144?

The notice covers 2,216 common shares of MYT Netherlands Parent B.V.

What is the approximate market value of the proposed MYTE share sale?

The aggregate market value is $16,287.60.

When is the MYTE share sale expected to occur?

The filing lists an approximate sale date of 07/09/2025.

What percentage of MYTE’s outstanding shares does the sale represent?

It represents roughly 0.0016 % of the 136,374,256 shares outstanding.

Were there any other recent insider sales disclosed?

Yes, a 10b5-1 sale of 10,000 shares on 05/14/2025 generating $100,457 is disclosed.

Which broker is handling the transaction?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.